Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease

MT Newswires Live10-20

Neurocrine Biosciences (NBIX) said Tuesday that it has initiated a phase 2 clinical study of NBI-1117567 to treat adults with mild to moderate Alzheimer's disease.

The biopharmaceutical company said the investigational compound is being evaluated as an adjunctive treatment for cognitive impairment in the disease.

The study will evaluate the whether NBI-1117567 can improve cognitive performance in adults with mild to moderate Alzheimer's disease who are receiving stable treatment with an acetylcholinesterase inhibitor.

The primary efficacy endpoint of the trial is the change from baseline in a Neuropsychological Test Battery composite score at week 12. Secondary endpoints include changes from baseline in ADAS-Cog13 and CDR Sum of Boxes at week 12.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment